Novacyt Confirms Adoption of All Resolutions at its AGM

On June 20, 2025, Novacyt SA, a molecular diagnostics company, announced the results of its Annual General Meeting held the previous day. All ordinary and several extraordinary resolutions were approved, including resolutions 10, 11, 15, 20, 22, and 24. Voting details are available on Novacyt's website.

Lyn Rees, Chief Executive Officer, stated that this approval strengthens the Board's flexibility in the face of a dynamic market. Novacyt is focused on a sustainable growth strategy through effective cost management and product innovation. Their approval supports growth initiatives, with a focus on creating value for shareholders.